BioSpace News Archive

Ractigen Therapeutics announces a formal collaboration with University Medical Center Utrecht, affiliated with Utrecht University.

Crystal Bio, an innovative spinout division of Crystal Pharmatech, is excited to announce Dr. Shiaw-Lin (Billy) Wu as its new co-founder and Chief Scientific Officer (CSO).

Enable Medicine, a leader in AI for biological research and drug discovery, announced today a research publication in Science Immunology that details a high-resolution spatial and transcriptomic atlas of IL-23 blockade in skin which provides insight on how different drug classes reprogram pathologic inflammation.

Asimov announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production.

Rise Therapeutics today announced that it has enrolled its first patient in its R-2487 Phase 1 rheumatoid arthritis clinical trial.

Molecular Designs, known for its market leadership in the design and production of molecular technologies, is pleased to announce the appointment of Michael Clark as its new Chief Executive Officer.

BIOTRONIK announced the milestone achievement of 100,000 implanted single lead implantable cardioverter-defibrillators equipped with DX Technology enabling direct atrial sensing for atrial fibrillation detection and monitoring.

ANGANY inc. announces the completion on schedule of its first clinical trial, assessing the safety and allergenicity of its therapeutic candidate against human allergy to cats.

Tourmaline Bio, Inc. announced the closing of its previously-announced underwritten public offering of 5,307,691 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 692,307 additional shares, at a public offering price of $32.50 per share.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Takeda received European Commission (EC) approval for HYQVIA® [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme’s ENHANZE® drug delivery technology as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy (CIDP) after stabilization with intravenous immunoglobulin therapy (IVIG).